Key result
Concomitant use of ticagrelor and ARBs significantly increased the frequency of dyspnea (21.4% vs 14.6% for ticagrelor without ARB) and renal adverse events.
Why the study?
Does concomitant use of ARBs with ticagrelor increase the risk of renal adverse events and dyspnea compared to ticagrelor without ARBs or clopidogrel?
Population
Patients treated with ticagrelor or clopidogrel
Comparison
Ticagrelor with concomitant angiotensin receptor… vs Ticagrelor without concomitant ARBs >50% of…
Design
Review
Authors
Loading...
May warrant renal monitoring with ticagrelor; leaves open interaction risks with common medications.
Observational
Does concomitant use of ARBs with ticagrelor increase the risk of renal adverse events and dyspnea compared to ticagrelor without ARBs or clopidogrel?
Absolute Event Rate: 21.4% vs 14.6%
Concomitant use of ARBs with ticagrelor may increase the risk of renal adverse events and dyspnea, suggesting a potential drug-drug interaction that warrants clinical attention.
DiNicolantonio et al. (2012) conducted an observational in Patients treated with ticagrelor or clopidogrel. Ticagrelor with concomitant ARBs vs. Ticagrelor without concomitant ARBs and clopidogrel was evaluated on Dyspnea. Concomitant use of ticagrelor and ARBs significantly increased the frequency of dyspnea (21.4% vs 14.6% for ticagrelor without ARB) and renal adverse events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: